Published in Lung on January 19, 2007
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer (2010) 1.11
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. Wien Med Wochenschr (2015) 0.75
Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer (2015) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Reporting results of cancer treatment. Cancer (1981) 28.83
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med (2002) 7.59
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med (1995) 6.44
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med (1991) 6.33
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol (1990) 3.20
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer (1993) 2.08
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol (2004) 2.08
Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma (2003) 1.59
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol (2003) 1.32
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol (1993) 1.29
Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol (2000) 1.21
Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer (1990) 1.08
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol (1994) 1.07
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2003) 1.05
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol (1998) 0.94
Small cell lung cancer. State-of-the-art therapy 1994. Chest (1995) 0.93
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol (1995) 0.93
A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol (1987) 0.92
Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group. Clin Oncol (R Coll Radiol) (1998) 0.75
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) (1995) 0.75
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Intracranial aneurysms: CT angiography and MR angiography for detection prospective blinded comparison in a large patient cohort. Radiology (2001) 2.21
Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review. Radiology (2000) 2.13
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) (2007) 2.02
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
What is the most sensitive non-invasive imaging strategy for the diagnosis of intracranial aneurysms? J Neurol Neurosurg Psychiatry (2001) 1.51
Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol (1994) 1.35
An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol (1988) 1.35
Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol (1992) 1.34
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res (1992) 1.27
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol (2007) 1.22
Id-1 delays senescence but does not immortalize keratinocytes. J Biol Chem (2000) 1.19
Patellar resurfacing in primary total knee replacement: a meta-analysis. J Bone Joint Surg Am (2012) 1.18
Exclusion of COL2A1 as a candidate gene in a family with Wagner-Stickler syndrome. J Med Genet (1990) 1.16
Course of Modic 1 six months after lumbar posterior osteosynthesis. Spine (Phila Pa 1976) (2003) 1.14
Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules. Cancer Chemother Pharmacol (1982) 1.08
Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC-Lung Cancer Study Group. Acta Oncol (1995) 1.05
The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett (1998) 1.04
Isolated extremity perfusion with DTIC. An experimental and clinical study. Anticancer Res (1983) 0.97
Community optometrist referral of those aged 65 and over for raised IOP post-NICE: AOP guidance versus joint college guidance--an epidemiological model using BEAP. Br J Ophthalmol (2011) 0.95
Development of comprehensive disease assessment in systemic vasculitis. Postgrad Med J (2008) 0.94
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer (2008) 0.92
Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol (2001) 0.92
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant (2008) 0.91
Renal involvement in systemic amyloidosis. Proc Eur Dial Transplant Assoc (1983) 0.91
Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol (1992) 0.91
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol (2007) 0.89
First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. Recent Results Cancer Res (1983) 0.89
Responses to gram negative enteric bacterial antigens by synovial T cells from patients with juvenile chronic arthritis: recognition of heat shock protein HSP60. J Rheumatol (1993) 0.88
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat (2008) 0.88
Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage. J Rheumatol (2001) 0.87
[Isolated liver perfusion with 5-fluorouracil (5-FU) in the human]. Chirurg (1982) 0.86
Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. Ann Oncol (2000) 0.84
Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. Crit Rev Oncol Hematol (2009) 0.83
[Conservative treatment of fistulas of the pancreas and the small intestine with somatostatin (author's transl)]. Ann Chir (1982) 0.83
Antibody producing capacity to the bacteriophage phi X174 in rheumatoid arthritis. Ann Rheum Dis (1987) 0.83
Power transcranial Doppler ultrasound in the detection of intracranial aneurysms. Stroke (2001) 0.82
Sjögren's syndrome after infection by Epstein-Barr virus. J Rheumatol (1990) 0.81
Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant (2009) 0.81
Is there an effect of acupuncture on the resting EEG? Complement Ther Med (2001) 0.80
Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematol Oncol (2011) 0.79
Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. Eur Respir J (1997) 0.77
Requirements and results of liver perfusion. Recent Results Cancer Res (1986) 0.77
Criteria for assessing disease activity in systemic lupus erythematosus. J Rheumatol (1989) 0.77
Therapeutic progress--review VI. Treatment of rheumatoid arthritis. J Clin Hosp Pharm (1982) 0.77
Dietary advice in systemic sclerosis: the dangers of a high fibre diet. Ann Rheum Dis (1998) 0.76
Impact of nasal continuous positive airway pressure treatment on quality of life in patients with obstructive sleep apnoea. Eur Respir J (1998) 0.76
Successful reimplantation of splenic tissue after neonatal abdominal trauma. Lancet (1980) 0.76
Regional perfusion with cis-platinum and dacarbazine. Recent Results Cancer Res (1983) 0.76
Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver. Cancer Chemother Pharmacol (2000) 0.76
HLA-DR4 and career prospects in rheumatology: is there a link? BMJ (1996) 0.75
Osseous metastases in breast cancer: radiographic monitoring of therapeutic response. Anticancer Res (2002) 0.75
[Method of demonstration of fresh myocardial infarction]. Thoraxchir Vask Chir (1973) 0.75
[Peripheral airway obstruction and closing volume (author's transl)]. Prax Pneumol (1975) 0.75
Azapropazone-associated antibodies. Vox Sang (1984) 0.75
Tumor markers for the diagnosis, prognosis, treatment and follow-up of gynaecological tumors. Bull Soc Sci Med Grand Duche Luxemb (1989) 0.75
[Legionnaires' disease in Austria]. MMW Munch Med Wochenschr (1979) 0.75
Are Albumin Levels a Good Predictor of Mortality in Elderly Patients with Neck of Femur Fractures? J Nutr Health Aging (2017) 0.75
Combination therapy in autoimmune disease: vasculitis. Springer Semin Immunopathol (2001) 0.75
Objectives and outcome of running an early inflammatory arthritis clinic. Baillieres Clin Rheumatol (1992) 0.75
Phase II trial of gemcitabine in advanced non-small-cell lung cancer. Wien Klin Wochenschr (1997) 0.75
[Brucellosis and Aujeszky's disease in a wild boar enclose. Case report]. Tierarztl Prax Ausg G Grosstiere Nutztiere (1999) 0.75
Diagnostic and prognostic importance of tumor markers in lung cancer. Suppl J Med Oncol Tumor Pharmacother (1988) 0.75
[Comparative computerized tomography cephalometric and pharyngometric studies of patients with severe and mild sleep apnea, and in a control group]. Pneumologie (1993) 0.75
[IgE-mediated allergies (type I allergies)--clinical aspects and therapy in adults]. Wien Klin Wochenschr (1993) 0.75
Cross-resistance of 5-fluorouracil-resistant colon carcinoma in vitro. Int J Clin Pharmacol Ther (2011) 0.75
Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease. Drugs (1994) 0.75
Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate (1999) 0.75
A screening method for sleep-apnoea detection. Eur Respir J Suppl (1990) 0.75
[Transcapillary distribution of various plasma proteins in pleural effusion]. Wien Z Inn Med (1973) 0.75
[Somatostatin in small intestine fistulas]. Chirurg (1980) 0.75
[Surgical treatment of lung abnormalities]. Chirurg (1980) 0.75
Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. Am J Clin Oncol (1991) 0.75
[The "Inpatient Vaccination" Project in upper Austria. Technical report]. Wien Med Wochenschr (1998) 0.75
Activity, damage and outcome in systemic vasculitis. Best Pract Res Clin Rheumatol (2001) 0.75
Nutritional care of the patient with HIV/AIDS. Nurs Stand (1996) 0.75
Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours. Bone Marrow Transplant (2008) 0.75
[Erosion-hemorrhage after tracheotomy. Truncus brachiocephalicus--prosthesis]. Chirurg (1976) 0.75
Assessing risk: are we being overcautious? Br J Psychiatry Suppl (1997) 0.75
Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy. Int J Clin Pharmacol Ther (2010) 0.75
Diagnostic and prognostic importance of tumor markers in lung cancer. Bull Soc Sci Med Grand Duche Luxemb (1989) 0.75
[Sleep apnea and the work site]. Pneumologie (1990) 0.75
Open- and closed-mindedness and recognition of visual humor. J Commun (1971) 0.75
[Antirheumatic agents in bronchial asthma]. MMW Munch Med Wochenschr (1979) 0.75
[Spirographic evaluation of obstructive ventilation disorders]. Wien Med Wochenschr (1975) 0.75
N-CPAP rejecters--a specific group of noncompliant patients with obstructive sleep apnea syndrome. Wien Klin Wochenschr (2001) 0.75
P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. Int J Oncol (1998) 0.75
[An acid-base blood-gas calculator (author's transl)]. MMW Munch Med Wochenschr (1975) 0.75
Tumor markers for the diagnosis, prognosis, treatment and follow-up of gynaecological tumors. Suppl J Med Oncol Tumor Pharmacother (1988) 0.75
[Practicability, effectiveness and tolerance of a standardized prepared theophylline infusion]. Acta Med Austriaca (1996) 0.75
[Computer experience and further developments in the respiratory function laboratory (author's transl)]. Med Klin (1975) 0.75
[Biliodigestive anastomoses in lesions and benign diseases of the efferent bile ducts]. Med Welt (1980) 0.75